Yoshino Hirofumi, Yonemori Masaya, Miyamoto Kazutaka, Tatarano Syuichi, Kofuji Satoshi, Nohata Nijiro, Nakagawa Masayuki, Enokida Hideki
Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
Department of Internal Medicine, Vontz Center, University of Cincinnati, College of Medicine, Ohio 45267-0508, USA.
Oncotarget. 2017 Mar 28;8(13):20881-20894. doi: 10.18632/oncotarget.14930.
Previous studies showed that five miRNAs (miR-885-5p, miR-1274, miR-210-3p, miR-224 and miR-1290) were upregulated the most in clear cell renal cell carcinoma (ccRCC). Our focus was to understand from a clinical standpoint the functional consequences of upregulating miR-210-3p. Towards this, we utilized the CRISPR/Cas9 gene editing system to deplete miR-210-3p in RCC cell lines (786-o, A498 and Caki2) and characterized the outcomes. We observed that miR-210-3p depletion dramatically increased tumorigenesis, including altering the morphology of A498 and Caki2 cells in a manner characteristic of epithelial-mesenchymal transition (EMT). These results were corroborated by in vivo xenograft studies, which showed enhanced growth of tumors from miR-210-3p-depleted A498 cells. We identified Twist-related protein 1 (TWIST1) as a key target of miR-210-3p. Analysis of the ccRCC patient data in The Cancer Genome Atlas database showed a negative correlation between miR-210-3p and TWIST1 expression. High TWIST1 and low miR-210-3p expression associated with poorer overall and disease-free survival as compared to low TWIST1 and high miR-210-3p expression. These findings suggest that renal cell carcinoma progression is promoted by TWIST1 suppression mediated by miR-210-3p.
先前的研究表明,五种微小RNA(miR-885-5p、miR-1274、miR-210-3p、miR-224和miR-1290)在透明细胞肾细胞癌(ccRCC)中上调最为显著。我们的重点是从临床角度了解上调miR-210-3p的功能后果。为此,我们利用CRISPR/Cas9基因编辑系统在肾癌细胞系(786-o、A498和Caki2)中去除miR-210-3p,并对结果进行了表征。我们观察到,去除miR-210-3p显著增加了肿瘤发生,包括以一种上皮-间质转化(EMT)特征性的方式改变A498和Caki2细胞的形态。体内异种移植研究证实了这些结果,该研究显示来自去除miR-210-3p的A498细胞的肿瘤生长增强。我们确定Twist相关蛋白1(TWIST1)是miR-210-3p的关键靶点。对癌症基因组图谱数据库中ccRCC患者数据的分析显示,miR-210-3p与TWIST1表达呈负相关。与低TWIST1和高miR-210-3p表达相比,高TWIST1和低miR-210-3p表达与较差的总生存期和无病生存期相关。这些发现表明,miR-210-3p介导的TWIST1抑制促进了肾细胞癌的进展。